Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

计划入组 500 人 · 首次发布于 2026 年 5 月 4 日

Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

计划入组 5 人 · 首次发布于 2019 年 4 月 30 日

TDXD in Metastatic HER2-Positive Breast Cancer

计划入组 25 人 · 首次发布于 2026 年 8 月 21 日

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

undisclosed epigenetic target therapeutic (metastatic breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Tucatinib and Trastuzumab Show Promise in HER2-Mutated Metastatic Breast Cancer

Evexta Bio and Roche Ink Clinical Collaboration to Evaluate Rupitasertib Plus Giredestrant in ESR1-Mutated Metastatic Breast Cancer

Relay Therapeutics and Pfizer Collaborate to Evaluate Novel Triplet Therapy for Metastatic Breast Cancer